Pharmakologische Wirkungen des Protamins Clupein

Zusammenfassung Das Protamin, Clupeinsulfat, besitzt schon in niedrigsten Konzentrationen die gleichen kolloid-osmotischen und adsorptiven Eigenschaften wie andere höhermolekulare Eiweißkörper. Bis zu 20 Clupeinsulfat verstärken die Kammertätigkeit des hypodynamen Froschherzens. Über 50 Clupeinsulfat bewirken systolischen Kammerstillstand. 0,5–5 Clupeinsulfat verstärken die Azetylcholinwirkung, größere Mengen setzen sie herab, erhöhen aber unter Umständen die Wirkungsdauer. Das Clupeinsulfat geht mit einigen höhermolekularen Eiweißkörpern Verbindungen ein, durch die diese Eiweißkörper eine Änderung in ihrer Löslichkeit, Dispersität und Adsorptionsfähigkeit erfahren.Mit 3 Textabbildungen (11 Einzelbildern).     

Supportivtherapie ist nicht alles,aber ohne Supportivtherapie ist alles nichts

Ohne Zusammenfassung     

Chromosomal evolution and tumor progression in a myxoid liposarcoma

A myxoid liposarcoma showed macroscopic, histologic, and cytogenetic heterogeneity. In one of three myxoid nodules and in the surrounding lipoma-like tumor tissue, the translocation t(12;16)(q13;p11), known to be specific for myxoid liposarcoma, was found as the sole chromosomal abnormality. In the other two nodules, additional rearrangements involving chromosomes 1, 12, and 16 were found. These aberrations were probably secondary to the primary t(12;16), and are cytogenetic evidence of clonal evolution. The complex chromosome aberrations were present in those tumor parts that had more malignant histology, indicating that the acquisition of secondary chromosomal aberrations parallels the histologic manifestations of tumor progression.     

Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

Summary Phosphonacetyl-l-aspartate (PALA), an inhibitor of aspartate transcarbamylase that depletes uridine nucleotide pools, selectively potentiates the antitumor activity of 5-fluorouracil (5-FU) in preclinical models. Due to the promising results we obtained using PALA/5-FU in colorectal cancer, we performed a phase II trial in patients presenting with advanced pancreatic cancer. PALA was given intravenously at 250 mg/m² on day 1, followed 24 h later by 2,600 mg/m² 5-FU given by 24-h infusion. Treatments were repeated weekly. A total of 41 patients who had not previously undergone chemotherapy were entered in the trial; of these, 35 were evaluable for response. Toxicity was generally mild to moderate; neurotoxicity (13/35) and diarrhea (8/35) predominated. Among the 35 patients, 1 achieved a complete response and 4, a partial remission, for an overall response rate of 14%. The median survival was 5.1 months. Pretreatment with PALA alone was not sufficient to enhance the activity of 5-FU in pancreatic cancer.Supported in part by grant CA 06927 from the National Cancer Institute     

Rupture of the posterior tibial tendon: CT and surgical findings

Computed tomography (CT) was performed in 42 patients with 49 clinically suspected tears of the posterior tibial tendon. Twenty-eight of the 49 suspected tears were subsequently surgically explored and repaired. Three patterns of tendon abnormalities were recognized on CT scans: type I-intact, hypertrophied, heterogeneous tendon; type II-attenuated tendon; and type III-absence of a portion of a tendon. Types I and II correlated with partial rupture seen during surgery, and type III correlated with complete rupture of the tendon. CT findings were accurate in 96% of the patients who underwent surgery. In four cases (14%), tendon rupture was seen on CT scans, but the extent of the injury was underestimated and the rupture was misclassified. Reactive periostitis of the distal tibia was seen in 71% of diseased tendons and may represent an important factor in the diagnosis of tendon rupture.